featured
Addition of Pembrolizumab to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial
JAMA Oncol 2023 Mar 16;[EPub Ahead of Print], LJ Bryan, C Casulo, PB Allen, SE Smith, H Savas, GL Dillehay, R Karmali, B Pro, KL Kane, LA Bazzi, JS Chmiel, BA Palmer, J Mehta, LI Gordon, JN WinterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.